Back to Journals » OncoTargets and Therapy » Volume 12

NACT + IMRT versus NACT + IMRT + CCRT in locoregionally advanced NPC patients: a retrospective study

Authors Chen X, Zhu X, Wang J, Liu J, Ji R

Received 10 August 2018

Accepted for publication 21 October 2018

Published 22 February 2019 Volume 2019:12 Pages 1553—1562

DOI https://doi.org/10.2147/OTT.S183483

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Jianmin Xu


Xialin Chen,1,2 Xiang Zhu,3 Jianfang Wang,1,2 Jianjiang Liu,1,2 Rong Ji4

1Department of Oncology, Shaoxing People’s Hospital, Shaoxing, Zhejiang 312000, China; 2Department of Oncology, Shaoxing Hospital of Zhejiang University, Shaoxing, Zhejiang 312000, China; 3Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, China; 4Department of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang 312000, China

Purpose: The outcomes and safety profiles of neoadjuvant chemotherapy (NACT) + intensity modulated radiotherapy (IMRT) or NACT + IMRT + concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients were retrospectively analyzed.
Patients and methods: Between 2010 and 2014, 125 patients with stage III–IVb NPC, who were treated with IMRT (36, 28.8%) or IMRT + CCRT (89, 71.2%) following NACT, participated in the research. There were grade 3–4 toxicities during NACT or radiotherapy (RT) in NACT + IMRT group and NACT + IMRT + CCRT group.
Results: MRI within 3 months demonstrated that no patient suffered with progressive disease, 116 patients (92.8%) achieved a response rate (RR) with the complete response (CR) rate of 70.4% (88/125) and partial response (PR) rate of 22.4% (28/125), and nine patients (7.2%) showed stable disease (SD) at the primary site and metastatic nodes. Compared with NACT + IMRT group, patients in NACT + IMRT + CCRT group did not show significantly better RR (93.3% vs 91.7%, P=1.00), CR rate (71.9% vs 66.7%, P=0.67), or PR rate (21.4% vs 25%, P=0.81). There was no significant difference in overall survival (OS, P=0.114), local relapse-free survival (LRFS, P=0.124), distant metastasis-free survival (DMFS, P=0.668) or progression-free survival (PFS, P=0.475) between NACT + IMRT group and NACT + IMRT + CCRT group. T classification (P=0.042) and N classification (P=0.021) were independent prognostic factors for DMFS.
Conclusion: To sum up, no significant difference was observed in combined RR, CR rate, LRFS, DMFS, PFS, or OS between the two groups.

Keywords: advanced nasopharyngeal carcinoma, intensity modulated radiotherapy, concurrent chemoradiotherapy, neoadjuvant chemotherapy


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]